Therapeutic options for patients with Hodgkin's disease who relapse after high-dose chemotherapy with autologous stem cell support are limited. Salvage chemotherapy is not curative, and allogeneic stem cell transplantation in this setting is associated with mortality rates of 40-65%. We report our institution's experience with second autologous transplants in this patient population. Five patients (median age 36) with relapsed Hodgkin's disease underwent a second autologous stem cell transplant at a median of 66 months after first transplant. Four patients received CBV, and one patient received BuCy as conditioning. Neutrophil and platelet engraftment occurred by days +10 and +16, respectively. All patients achieved a complete response, and no relapses have occurred after a median follow-up of 42 months. All four patients who received CBV developed interstitial pneumonitis, and two patients died of pulmonary complications 37 and 48 months following second transplant. Three patients remain alive and disease-free 41, 42 and 155 months after second transplant. These data indicate that second autologous transplantation should be considered for selected patients who relapse after a prolonged response to first autologous transplant. However, BCNU pneumonitis is the major toxicity in patients who have undergone previous mantle radiation and received busulfan with first transplant. 
Hodgkin's disease is one of the most chemosensitive and curable malignancies with overall long-term survival rates of 75%. 1 [3] [4] [5] [6] However, therapeutic options for patients with Hodgkin's disease who relapse following autologous transplant are limited. Agents such as gemcitabine and navelbine have shown promise in relapsed or refractory Hodgkin's disease, but these therapies are unlikely to be curative. [7] [8] [9] Allogeneic hematopoietic stem cell transplantation offers long-term survival to approximately 15% of patients but is associated with a treatment-related mortality rate of 30-65%. [10] [11] [12] Thus, many transplant centers are reluctant to consider allogeneic transplantation in a patient who has failed autologous transplantation. Second autologous transplant is rarely considered following failure of a first transplant to achieve cure. However, in a patient who has enjoyed a relatively long response to his or her first transplant, a second autologous transplant may be a viable alternative. 13, 14 We report here the results of second autologous transplants in five patients with Hodgkin's disease who had relapsed after high-dose therapy with autologous stem cell support.
Patients and methods

Study population
Five patients whose Hodgkin's disease had relapsed despite high-dose therapy with autologous stem cell support underwent a second autologous transplant at The Ohio State University (OSU)/Arthur James Cancer Center between 1988 and 1998. Pathology specimens were reviewed at OSU to confirm the diagnosis of relapsed Hodgkin's disease, and each patient's disease status entering transplant was evaluated.
Stem cell source
Two patients underwent bone marrow harvest. Four patients received high-dose VP-16 2000 mg/m 2 , followed by G-CSF support for stem cell mobilization, as previously described, 15 and collection of autologous peripheral blood stem cells (PBSC). One patient received marrow alone, three patients received PBSC alone, and one patient received both marrow and PBSC. Table 1 Characteristics of individual patients (n ϭ 5)
Age at 2nd SCT (years)  32  44  25  39  36  Stage at initial diagnosis  II-A  I-A  II-A  III-A  II-B  Therapy at diagnosis  CT+RT  RT  CT+RT  CT  CT+RT  Duration of CR1 (months)  10  156  17  10  24  Prior mediastinal or mantle radiation  Yes  Yes  Yes  Yes  Yes  Interval from Dx to 1st SCT (months)  87  171  51  36  79  Duration of response to 1st SCT (months)  8  59  87  28  10  Interval from 1st SCT to 2nd SCT (months)  12  66  90  75  46  Relapse at 2nd SCT  5th  3rd  3rd  4th  4th  Stage entering 2nd SCT  II  II  III  IV 
Results
Study population and first transplant
Five patients (four male, one female) with a median age of 36 years (range 25-44 years) underwent second autologous transplant for relapsed Hodgkin's disease. Characteristics of individual patients are depicted in Table 1 , and results are summarized in Table 2 . At time of initial diagnosis, one patient had stage I disease, three were stage II, and one was stage III; only one patient had B symptoms. As initial treatment, patients had received radiation therapy alone (one), chemotherapy alone (one), or combined modality therapy (three); all patients achieved complete remission (CR). Median duration of first CR was 17 months (range 10-156 months), and median time from initial diagnosis to first transplant was 79 months (range 36-171 months). All patients received mediastinal or mantle radiation, as well as four to eight cycles of bleomycin in the ABVD chemotherapy regimen, as part of initial or salvage treatment.
First autologous transplant was performed after second relapse (four) or fourth relapse (one). At the time of first transplant, one patient was in CR, three were in partial remission (PR), and one was taken directly to transplant without cytoreductive therapy. Patients received one of the following conditioning regimens for the first transplant: BuCy (two); busulfan, cyclophosphamide and VP-16 (two); or cyclophosphamide, thiotepa and VP-16 (one). The autologous stem cell source for first transplants consisted of marrow alone (three patients) or marrow and PBSC (two). All patients achieved a CR following first transplant. The median duration of response was 28 months (range 8-87 months).
Second autologous transplant
Patients underwent second autologous transplantation at a median of 66 months (range 12-90 months) after first transplant, as shown in Table 2 . Two of the five patients received one or more therapies, with subsequent relapse, between the first and second transplants. Three patients entered transplant with stage II disease, one was stage III, and one was stage IV. The second transplant was performed after third relapse (two patients), fourth relapse (two) or fifth relapse (one). Four patients were in PR, and one patient was taken directly to second transplant without cytoreductive therapy.
Engraftment
Patients were discharged home following second transplant a median of 11 days (range 10-53 days) after reinfusion of autologous stem cells (Table 3) . Recovery of neutrophils Ͼ500/l occurred at a median of 10 days (range 9-38 days), and four of five patients had neutrophil recovery by day +10. Platelet recovery Ͼ20 000/l occurred at a median of 16 days (range 16 to Ͼ100 days); four of five patients recovered platelet counts by day +24.
Toxicity
The major treatment-related toxicity was interstitial pneumonitis, which occurred in four of five patients (Table 3 ). All four patients who received the CBV regimen as conditioning for second transplant developed pneumonitis within 3 months of the transplant date. The single patient who received BuCy did not experience pulmonary complications; interestingly, he had developed bleomycin pulmonary toxicity with his initial therapy and, consequently, had not received BCNU as conditioning for first transplant. Two patients who developed BCNU pneumonitis responded quickly to steroid therapy. However, two patients developed progressive pulmonary fibrosis that eventually resulted in death, as described in the following section. No veno-occlusive disease (VOD) was observed; one patient, who had developed severe VOD to BuCy during her initial transplant, suffered no liver toxicity during her second transplant. Infectious complications were limited to bacteremia, which were documented by blood cultures in three of five patients. One patient developed E. coli sepsis that was managed with intravenous antibiotic therapy. No viral or fungal infections were observed. One patient developed myelodysplasia (MDS) 31 months after his second transplant (77 months after first transplant).
Response and survival
All five patients achieved CR following second autologous transplant (Table 3) . Median follow-up is 42 months (range 37-155 months) after second transplant, and no relapses have been seen. As mentioned previously, one patient developed MDS after second transplant and recently underwent a non-myeloablative matched unrelated donor allogeneic stem cell transplant for acute myelogenous leukemia (AML). Two patients died of complications related to pulmonary toxicity. One patient died of interstitial pneumonitis and progressive respiratory failure, which was not treated, 48 months after second transplant. A second patient died of complications of an open lung biopsy 37 months following second transplant. He had developed a pneumonia that prompted a thoracoscopic lung biopsy 4 months prior to his death. Due to complications during surgery, he was maintained on 100% oxygen for several days. He developed a bronchopleural fistula, persistent pneumothorax and progressive respiratory failure that resulted in his demise. Of note, both patients had returned to their local community hospitals and were not receiving medical care at OSU at the time they developed the complications that eventually led to their death. Three patients remain alive and free of Hodgkin's disease at a median time of 42 months (range 41-155 months) after second transplant and 153 months (range 134-167 months) after initial diagnosis.
Discussion
The role of second transplants in relapsed hematologic malignancies remains unclear. Attempts to perform full allogeneic stem cell transplants in patients who have undergone previous transplants have been complicated by high rates of treatment-related mortality. [16] [17] [18] In a large retrospective analysis of second allogeneic transplants for leukemia, the treatment-related mortality rate was 41%; this figure increased to 69% for patients who relapsed less than 6 months after initial transplant. 18 Our results indicate that a second autologous transplant is an appropriate option for selected patients with relapsed Hodgkin's disease; however, interstitial pneumonitis is the major complication.
Our five patients had slowly progressive disease; second autologous transplant was performed at medians of 66 months (range 12-90 months) after first transplant and 125 months (range 98-237 months) after initial diagnosis. Nonpulmonary treatment-related toxicity was minimal. Four of five patients achieved neutrophil and platelet engraftment by days +10 and +24, respectively. One patient developed E. coli sepsis that was managed with intravenous antibiotic therapy, but no viral or fungal complications were observed. None of the five patients, including one who had developed VOD during her first transplant, developed VOD following second transplant. Secondary MDS occurred in one patient.
Pulmonary complications were the major toxicity and contributed to both deaths. All five patients had received prior mediastinal or mantle radiation, as well as four to eight cycles of ABVD. Four patients who received CBV as second transplant conditioning all developed interstitial pneumonitis, whereas the single patient who received BuCy did not. That patient had not received BCNU as conditioning for his first transplant due to bleomycin pulmonary toxicity. Thus, BCNU pneumonitis appears to be the major cause of morbidity and mortality. BuCy or etoposide-based regimens such as high-dose ifosfamide, carboplatin and VP-16 (ICE) should be considered as alternative preparative conditioning regimens. As mantle radiation is increasingly replaced by combined modality therapy using limited involved field radiation for limited stage Hodgkin's disease, transplant-induced pneumonitis may become more manageable.
The results of this small study indicate that second autologous transplant can achieve remissions of significant duration in selected patients with slowly progressive disease. None of our five patients relapsed with a median follow-up of 42 months. Although patients were in third or subsequent relapse at time of second transplant, all four patients who received cytoreductive therapy prior to transplant achieved PR. Thus, dose-intensive chemotherapy achieved durable remissions in multiply relapsed patients in whom standarddose therapy still yielded a measurable response. However, this approach is unlikely to work for patients with rapidly relapsing disease or no significant remission to initial transplant.
The European Blood and Bone Marrow Transplant (EBMT) registry published the results of 34 double transplants, 12 of which were performed in patients with Hodgkin's disease.
14 With a median follow-up of 18.5 months, six of 12 patients died of Hodgkin's disease, and two died of treatment-related mortality. Patients who achieved only PR or were refractory to first transplant fared particularly poorly; four of five died of progressive Hodgkin's disease. Of note, the median interval from first to second transplant was only 11 months. Thus, patients who are less than 12 months from first transplant are unlikely to benefit from second autologous transplant. Interestingly, only two of 34 patients died of pneumonitis. Both patients had received BCNU, VP-16, cytarabine and melphalan (BEAM) as conditioning for first transplant, followed by total body irradiation (TBI) as part of second transplant conditioning. Only five of 34 patients received busulfan with first or second transplant conditioning; it is not known how many patients received mediastinal or mantle radiation as part of prior therapy.
Time to relapse is the most important predictor of response to transplantation or other therapies for relapsed Hodgkin's disease. Complete remissions lasting longer than 2 years predict for better outcome to salvage therapy. A retrospective analysis of 25 patients who relapsed after a CR of greater than 24 months showed an expected 8 year overall survival of 82%. 19 However, our longest survivor, who is alive and disease-free 155 months following second transplant, experienced remissions of only 10 and 8 months, respectively, to initial therapy and first transplant. Similarly, three of four EBMT patients who remained alive in CR underwent second transplant within 12 months of first transplant, and the longest survivor (54 months) achieved only PR to his first transplant.
14 Thus, responses lasting less than 12 months to first transplant should not necessarily exclude patients from consideration for second autologous transplant.
The optimal therapy for relapsed Hodgkin's disease after autologous transplant is unclear; it is not known whether such patients benefit more from second autologous transplant or non-myeloablative allogeneic transplant. 20 The EBMT results indicate that second autologous transplants can be performed with minimal treatment-related mortality. There are very limited data regarding the regimen-related toxicity of non-myeloablative allogeneic transplants in this patient population. Such transplants differ greatly in myeloablative and immunosuppressive potential, and morbidity from graft-versus-host disease (GVHD) and infection may vary depending on the conditioning regimen. Given the relatively limited data supporting a graft-versus-lymphoma (GVL) effect in Hodgkin's disease, second autologous transplant may be a more attractive option than non-myeloablative allogeneic transplant. However, non-myeloablative sibling donor transplants may be preferable for patients who relapse within 12 months of first autologous transplant or are at increased risk of interstitial pneumonitis.
In summary, the results of our study suggest that a second course of high-dose chemotherapy can achieve a significant remission interval in selected patients. However, great care must be taken to select patients who are likely to respond and to minimize pulmonary complications in patients who have received prior chest radiation. Prior exposure to high-dose busulfan and the dose intensity of BCNU may also be important factors in identifying patients at highest risk of pneumonitis following second transplant.
